Details of the Drug Combination

General Information of Drug Combination (ID: DC5EN94)

Drug Combination Name
Linezolid Cilastatin
Indication
Disease Entry Status REF
Bacterial Pneumonia Phase 3 [1]
Component Drugs Linezolid   DMGFPU2 Cilastatin   DME2H5T
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Linezolid
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Skin infection 1F28-1G0Z Investigative [2]
Linezolid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA) TTLFGBV NOUNIPROTAC Binder [7]
------------------------------------------------------------------------------------
Linezolid Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Activity [8]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------
Indication(s) of Cilastatin
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Endometritis N.A. Approved [5]
Peritonitis N.A. Approved [5]
Pelvic inflammatory disease GA05 Investigative [5]
Cilastatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dehydropeptidase I (DPEP1) TTYUENF DPEP1_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Cilastatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dipeptidase 1 (DPEP1) OTVR8V1L DPEP1_HUMAN Decreases Activity [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02493764) Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
2 Linezolid FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200222.
4 Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12.
5 Cilastatin FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5166).
7 Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
8 Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.
9 Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31.
10 Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet. 2019 Feb;51(2):230-236.